Published in Lab Business Week, October 9th, 2005
The funds raised will support the continued development of the company's lead product candidate, Alpharadin, through its ongoing phase II clinical trials and into pivotal phase III trials as a potential new treatment for bone metastases arising from primary prostate cancer.
Alpharadin, is a bone-seeking experimental radiopharmaceutical based on the alpha particle emitter radium-223.
The syndicate of international investors included new investors HealthCap, Advent Venture Partners and SR One. Existing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.